Biomarkers of neoadjuvant/adjuvant chemotherapy for breast cancer

Inomata, Takayuki; Kajiwara, Yukiko; Zhu, Yidan; Iha, Shigemichi

doi:10.21037/cco.2020.01.06

Cited by 47 publications

(38 citation statements)

References 40 publications

(56 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, it is more reasonable to divide patients into low (<50%) and high (≥50%) groups. 20,[23][24][25][26][27][28][29][30][31] Previous studies have reported that low TIL cases exhibited significantly lower ADC values than high TIL cases. 32,35 Interestingly, this is not consistent with our results, as these previous studies excluded the non-mass-like lesions, and as the differences in the size and placement of ROIs may change the ADC values.…”

Section: Discussionmentioning

confidence: 98%

“…Increasing evidence shows the extent of which TILs are known to have predictive value for NAC and prognostic value in breast cancer, especially in TNBC and HER2-positive breast cancer patients. [23][24][25][26][27][28][29][30][31] Therefore, an accurate preoperative evaluation method of TIL level from noninvasive imaging data may help guide treatment regimens. Our study demonstrated that a radiomics nomogram based on preoperative MRI that incorporates optimal clinical factors and a radiomics signature exhibited the best performance for the evaluation of TIL level.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluating Tumor‐Infiltrating Lymphocytes in Breast Cancer Using Preoperative MRI‐Based Radiomics

Bian

Lin

et al. 2021

Magnetic Resonance Imaging

View full text Add to dashboard Cite

Background Evaluating tumor‐infiltrating lymphocytes (TILs) in patients with breast cancer using radiomics has been rarely explored. Purpose To establish a radiomics nomogram based on dynamic contrast‐enhanced (DCE) magnetic resonance imaging (MRI) for preoperatively evaluating TIL level. Study Type Retrospective. Population A total of 154 patients with breast cancer were divided into a training cohort (N = 87) and a test cohort (N = 67), who were further divided into low TIL (<50%) and high TIL (≥50%) subgroups according to the histopathological results. Field Strength/Sequence 3.0 T; axial T2‐weighted imaging (fast spin echo), diffusion‐weighted imaging (spin echo‐echo planar imaging), and the volume imaging for breast assessment DCE sequence (gradient recalled echo). Assessment A radiomics signature was developed from the training dataset and independent risk factors were selected by multivariate logistic regression to build a clinical model. A nomogram model was built by combining radiomics score and risk factors. The performance of the nomogram was assessed using calibration curves and decision curves. The area under the receiver operating characteristic (ROC) curve, accuracy, sensitivity, and specificity were calculated. Statistical Tests The least absolute shrinkage and selection operator, univariate and multivariate logistic regression analysis, t‐tests and chi‐squared tests or Fisher's exact test, Hosmer–Lemeshow test, ROC analysis, and decision curve analysis were conducted. P < 0.05 was considered statistically significant. Results The radiomics signature and nomogram model exhibited better calibration and validation performance in the training (radiomics: area under the curve [AUC] 0.86; nomogram: AUC 0.88) and test (radiomics: AUC 0.83; nomogram: AUC 0.84) datasets compared with clinical model (training: AUC 0.76; test: AUC 0.72). The decision curve demonstrated that the nomogram model exhibited better performance than the clinical model, with a threshold probability between 0.15 and 0.9. Data Conclusion The nomogram model based on preoperative MRI exhibited an excellent ability for the noninvasive evaluation of TILs in breast cancer. Level of Evidence 4 Technical Efficacy Stage 2

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Evaluating Tumor‐Infiltrating Lymphocytes in Breast Cancer Using Preoperative MRI‐Based Radiomics

Bian

Lin

et al. 2021

Magnetic Resonance Imaging

View full text Add to dashboard Cite

show abstract

“…The combined application of docetaxel, cyclophosphamide and epirubicin can significantly improve the effect of chemotherapy, increase the CR rate of tumor and enhance the survival of relevant patients. In addition to a role in killing tumor cells, neoadjuvant chemotherapy can also promote the transformation of tumor cells into normal breast cells, so as to gradually restore the expression of ER, HER-2, SATB1 and other indexes to the normal range 17 However, it should be noted that the immune dysfunction caused by chemotherapy will also result in immunosuppression of patients and reduce the therapeutic effect. In view of previous investigation, Pop et al 18 believed that neoadjuvant chemotherapy combined with immunotherapy could achieve a relatively higher pathological complete remission rate.…”

Section: Discussionmentioning

confidence: 99%

Clinical curative effect of neoadjuvant chemotherapy combined with immunotherapy and its impact on immunological function and the expression of ER, PR, HER-2 & SATB1 in HER-2-Positive breast cancer patients

Chen¹,

Sang²,

Chen³

et al. 2022

Pak J Med Sci

View full text Add to dashboard Cite

Objective: To evaluate the clinical curative effect of neoadjuvant chemotherapy combined with immunotherapy and its impact on immunological function and the expression of ER, PR, HER-2 and SATB1 in HER-2-positive breast cancer patients. Methods: The subjects of study were 80 patients with HER-2-positive breast cancer. Enrolled patients were randomly divided into two groups, with 40 cases in each group at The Fourth Affiliated Hospital of Hebei Medical University from March 2018 from March 2021. Patients in the control group were provided with neoadjuvant chemotherapy using TAC regimen merely; while those in the study group received oral administration of Apatinib Mesylate (500mg/d; three weeks a cycle) on the basis of the TAC regimen. Further comparative analysis was performed focusing on the therapeutic effect and adverse drug reaction rate of the two groups; levels of CD3+, CD4+, CD8+ and CD4+/CD8+ of T lymphocyte subsets in the two groups before and after treatment; as well as the expressions of ER, PR, HER-2 and SATB1 in the two groups before and after treatment. Results: The total response rate was 77.5% and 55% in the study group and the control group, respectively, with an obviously better outcome in the former group than that in the latter group (p=0.03). Meanwhile, the incidence of adverse reactions was 40% in the study group and 45% in the control group, without statistical difference (p=0.65). There were statistically significant differences that the levels of CD3+, CD4+, and CD4+/CD8+ in the study group were significantly higher when compared with those in the control group after treatment (CD3+, p=0.00; CD4+, p=0.02; CD4+/CD8+, p=0.00); while no evident change was observed in the level of CD8+ (p=0.88). After treatment, the positive expression rates of ER, HER-2 and SATB1 were remarkably lower in the study group than those in the control group, showing statistically significant differences (ER, HER-2, p=0.03; SATB1, p=0.02). However, there was no statistically significant difference in the positive expression rate of PR between the study group and the control group (P=0.80). Conclusions: Neoadjuvant chemotherapy combined with immunotherapy has significant effect on the treatment of HER-2-positive breast cancer patients. It can result in the significant enhancement of T lymphocyte function, obvious improvement in the negative converse rates of ER, HER-2 and SATB1, and no evident increase in the adverse drug reactions. The proposed therapeutic approach is safe, effective, and have certain clinical value. doi: https://doi.org/10.12669/pjms.38.3.5199 How to cite this:Chen Z, Sang M, Geng C, Hao W, Jia H. Clinical curative effect of neoadjuvant chemotherapy combined with immunotherapy and its impact on immunological function and the expression of ER, PR, HER-2 and SATB1 in HER-2-Positive breast cancer patients. Pak J Med Sci. 2022;38(3):---------. doi: https://doi.org/10.12669/pjms.38.3.5199 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

show abstract

“…In the past decades, more and more biomarkers have been found for the diagnosis and treatment of cancer [22,23]. However, the key regulatory factors in BRCA microenvironment and changes of TME in BRCA progression are yet to be clari ed.…”

Section: Discussionmentioning

confidence: 99%

CD1C is associated with Breast Cancer Prognosis and Immune Infiltrates

Chen

Zhang

Lei

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Tumor microenvironment (TME) in breast cancer has a vital role in occurrence, development, and therapeutic responses. However, immune and stroma constituents in TME are major obstacles to understanding and treating breast cancer. We evaluated the significance of TME related genes in breast cancer.Methods: Invasive breast cancer (BRCA) samples were retrieved from TCGA and GEO databases. Stroma and immune scores of samples as well as the proportion of tumor infiltrating immune cells (TICs) were calculated using ESTIMATE and CIBERSORT algorithms. TME-related differentially expressed genes (DEGs) were analyzed by protein interaction (PPI) network and univariate Cox regression to determine CD1c as hub gene. Subsequently, the prognostic value of CD1c, its response to immunotherapy and its mechanism in TME were further studied.Results: In BRCA, DEGs were identified to identify CD1C as hub gene. The differential expression level of CD1C in BRCA patients and the correlation between prognosis and clinical features were verified based on TCGA database and immunohistochemical staining (IHC) results. Enrichment analysis of GSEA and GSVA showed that CD1C take participate in immune-associated signaling pathways. CIBERSORT showed that CD1C levels were associated with tumor immune infiltrating cells (TILs), such as different kinds of T cells. Gene co-expression analysis showed that CD1C and most of immune-associated genes were co-expressed in BRCA. In renal cell carcinoma, patients with high expression of CD1C have better effect of immunotherapy.Conclusion: CD1C is an important part of TME and participates in immune activity regulation in breast tumors. CD1C is expected to become a prognostic marker and a new treatment target for breast cancer.

show abstract

Biomarkers of neoadjuvant/adjuvant chemotherapy for breast cancer

Cited by 47 publications

References 40 publications

Evaluating Tumor‐Infiltrating Lymphocytes in Breast Cancer Using Preoperative MRI‐Based Radiomics

Evaluating Tumor‐Infiltrating Lymphocytes in Breast Cancer Using Preoperative MRI‐Based Radiomics

Clinical curative effect of neoadjuvant chemotherapy combined with immunotherapy and its impact on immunological function and the expression of ER, PR, HER-2 & SATB1 in HER-2-Positive breast cancer patients

CD1C is associated with Breast Cancer Prognosis and Immune Infiltrates

Contact Info

Product

Resources

About